Merck stock slips after report says MRK stepped back from Revolution Medicines talks
Merck shares fell 0.6% to $107.57 after reports said talks to buy Revolution Medicines stalled over price. Revolution stock dropped 17%. The potential $28–32 billion deal would have given Merck access to Revolution’s late-stage cancer drug. Investors await Merck’s Feb. 3 earnings call for updates on future deals and 2026 guidance.